Surgical interventions for focal progression of advanced gastrointestinal stromal tumors during imatinib therapy

International Journal of Clinical Oncology

Volumn 12, Issue 3, 2007, Pages 212-217

  Hasegawa, Junichi ^a   Kanda, Tatsuo ^b   Hirota, Seiichi ^c   Fukuda, Masafumi ^d   Nishitani, Akiko ^a,c   Takahashi, Tsuyoshi ^a   Kurosaki, Isao ^b   Tsutsui, Shusaku ^e   Hatakeyama, Katsuyoshi ^b   Nishida, Toshirou ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NIIGATA UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

Gastrointestinal stromal tumor; Imatinib mesylate; Molecular target therapy; Resistance; Surgical interventions

Indexed keywords

IMATINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE LEAKAGE; CANCER GROWTH; CANCER RESISTANCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CONVALESCENCE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; HUMAN; ILEUS; LIVER ABSCESS; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SMALL INTESTINE TUMOR; STOMACH TUMOR; SURGICAL INFECTION; SURGICAL MORTALITY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PIPERAZINES; PYRIMIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34250632828     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-007-0657-y     Document Type: Article

References (20)

1. T Nishida S Hirota 2000 Biological and clinical review of stromal tumors in the gastrointestinal tract Histol Histopathol 15 1293 1301
2. RP DeMatteo MC Heinrich WM El-Rifai 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466 477
3. RP DeMatteo JJ Lewis D Leung 2002 Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival Ann Surg 231 51 58
4. PJ Roberts B Eisenberg 2001 Clinical presentation of gastrointestinal stromal tumors and treatment of operative disease Eur J Cancer 38 S37 38
5. AT Van Oosterom I Judson J Verweij 2001 Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study Lancet 358 1421 1423
6. H Joensuu PJ Roberts M Sarlomo-Rikala 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056
7. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480
8. J Verweji PG Casali J Zalcberg 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomized trial Lancet 364 1127 1134
9. C Rankin M von Mehren C Blanke 2004 Continued prolongation of survival by imatinib with metastatic GIST. Update of results from North American Intergroup phase III study S0033 (abstract) Proc Am Soc Clin Oncol 23 815
10. GD Demetri R Benjamin CD Blanke 2004 Optimal management of patients with gastrointestinal stromal tumor (GIST) - expansion and update of NCCN Clinical Practice Guidelines J Natl Compr Canc Netw 2 S1 S26
11. JY Blay S Bonvalot P Casali 2005 Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspices of ESMO Ann Oncol 16 566 578
12. JR Zalcberg J Verweji PG Casali 2004 Outcome of patients with advanced gastro-intestinal stromal tumours (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD) - an international, intergroup study of EORTC, ISG and AGITG (abstract) Proc Am Soc Clin Oncol 23 815
13. GD Demetri AT van Oosterom M Blackstein 2005 Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST (abstract) Proc Am Soc Clin Oncol 23 308
14. RG Maki JA Fletcher MC Heinrich 2005 SU11248 in patients with imatinib-resistant GIST: results from a continuation trial (abstract) Proc Am Soc Clin Oncol 23 818
15. S Bauer JT Hartmann M de Wit 2005 Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib Int J Cancer 117 316 325
16. A Gronchi M Fiore R Bertulli 2005 Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST) (abstract) Proc Am Soc Clin Oncol 23 825
17. P Rutkowski Z Nowecki P Nyckowski 2005 Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy (abstract) Proc Am Soc Clin Oncol 23 825
18. P Hohenberger C Langer S Pistorius 2006 Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) (abstract) Proc Am Soc Clin Oncol 24 520s
19. LL Chen M Sabripour RHI Andtbacka 2005 Imatinib resistance in gastrointestinal stromal tumors Curr Oncol Rep 7 293 299
20. NG Eng-hen RE Pollock MF Munsell 1992 Prognostic factors influencing survival in gastrointestinal leiomyosarcomas Ann Surg 215 68 77